



Information on the compensation of corporate officers

(in application of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code)

The combined general meeting of MaaT Pharma (the “**Company**”) which was held on May 31, 2022 at 10 a.m. at the registered office of the Company located 70 avenue Tony Garnier – 69007 Lyon, approved the resolution relating to the compensation policy for corporate officers in respect of the 2022 financial year (*Say on Pay ex-ante*), as well as the resolution relating to the information mentioned in I. of article L. 22-10-9 of the French Commercial Code (*Code de commerce*) relating to the compensation paid and/or granted to corporate officers in respect of the financial year ending December 31, 2021 (so-called “global” *Say on Pay ex-post*).

Pursuant to the provisions of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code, this information is presented below, supplemented for information purposes by the results of the votes on the resolutions relating to the individual compensation paid and/or allocated to the Company's corporate officers in respect of the financial year ending December 31, 2021 (so-called “individual” *Say on Pay ex-post*).

Resolution	Description	Results of the votes	Corresponding section in the 2021 Annual Financial Report (AFR)
THIRTEENTH RESOLUTION	Approval of the compensation policy for the chairman of the Board of Directors and the directors for the 2022 financial year	Approved by 99,245%	Corporate Governance Report (Section B of the AFR); Paragraph 5.1 (<i>Compensation policy for corporate officers</i>)
FOURTEENTH RESOLUTION	Approval of the compensation policy for the chief executive officer and/or any other executive corporate officer for the 2022 financial year	Approved by 99,229%	Corporate Governance Report (Section B of the AFR); Paragraph 5.1 (<i>Compensation policy for corporate officers</i>)
FIFTEENTH RESOLUTION	Approval of the information relating to the remuneration of corporate officers for the year 2021 mentioned in I of Article L. 22-10-9 of the French Commercial Code	Approved by 99,999%	Corporate Governance Report (Section B of the AFR); Paragraph 5 (<i>Compensation and benefits</i>)
SIXTEENTH RESOLUTION	Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or	Approved by 99,989%	Corporate Governance Report (Section B of the AFR); Paragraph 5 (<i>Compensation and benefits</i>)

	assigned during the year ended to Jean-Marie Lefevre, Chairman of the Board of Directors		
SEVENTEENTH RESOLUTION	Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended to Hervé Affagard, Chief Executive Officer	Approved by 99,227%	Corporate Governance Report (Section B of the AFR); Paragraph 5 (Compensation and benefits)

* * *

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.

The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.



MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Contacts

MaaT Pharma – Investor relations

Hervé AFFAGARD
 Co-Founder and CEO
 Siân Crouzet, COO/ CFO
 +33 4 28 29 14 00
invest@maat-pharma.com

MaaT Pharma -media relations

Pauline RICHAUD
 Senior PR & Corporate
 Communications Manager
 +33 6 07 55 25 36
prichaud@maat-pharma.com

Trophic Communications - Corporate and medical Communications

Jacob VERGHESE or
 Gretchen SCHWEITZER
 +49 89 23 88 77 31
maat@trophic.eu

